VIMIZIM (ELOSULFASE ALFA)
VIMIZIM (ELOSULFASE ALFA) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: VIMIZIM; Generic name: ELOSULFASE ALFA; Drug class: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC].
| Brand name | VIMIZIM |
|---|---|
| Generic name | ELOSULFASE ALFA |
| Drug class | Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] |
| Manufacturer | BioMarin Pharmaceutical Inc. |
| Used for | 1 INDICATIONS AND USAGE VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). VIMIZIM is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Administration of VIMIZIM should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. ( 2.1 ) 2 mg per kg body weight administered once every week as an intravenous infusion over a minimum of 3.5 to 4.5 hours, based on infusion volume. ( 2.2 , 2.4 ) See the full prescribing information for administration modifications due to hypersensitivity reactions. ( 2.3 ) 2.1 Important Administration Instructi |
| Warnings | WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS and RISK OF ACUTE RESPIRATORY COMPLICATIONS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscit |
| Active ingredient(s) | ELOSULFASE ALFA |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0caa2565-12b2-0ad0-1f9a-273e81c3d4cc |